Brief: Centessa Pharmaceuticals Says Positive Topline Data From Proof-Of-Concept Study Of Serpinpc In Severe Hemophilia A & B Patients Not On Prophylaxis
09/09/2021 13:07
Sept 9 (Reuters) - Centessa Pharmaceuticals PLC 260y.F :
* CENTESSA PHARMACEUTICALS- POSITIVE TOPLINE DATA FROM
PROOF-OF-CONCEPT STUDY OF SERPINPC IN SEVERE HEMOPHILIA A & B
PATIENTS NOT ON PROPHYLAXIS
* CENTESSA PHARMACEUTICALS PLC - SERPINPC OBSERVED TO BE
WELL-TOLERATED
Source text for Eikon: ID:nGNX3wYngp
Further company coverage: 260y.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Centessa Pharmaceuticals
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Acquisition Of Centessa By Lilly Approved By The High Court Of Justice Of England And Wales
Street View: Lilly's $7.8 billion Centessa buyout validates sleep‑drug market
Press Digest: New York Times business news - April 1